BioCentury
ARTICLE | Product Development

Turning up the heat(shock)

OncoGenex hopes OGX-427 heat shock inhibitor will block cancer drug resistance

February 20, 2012 8:00 AM UTC

The majority of cancer therapeutics directed against heat shock proteins are focused on Hsp90. OncoGenex Pharmaceuticals Inc. expects its OGX-427, a first-in-class Hsp27 inhibitor, will elicit fewer side effects and will help prevent resistance in combination with other cancer therapies.

OncoGenex presented the first clinical efficacy data for OGX-427 in castration-resistant colorectal cancer (CRPC) at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco this month...